Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
gosox12, have you tried calling the company to get your answers? The 12/31/2020 10-K Annual Report shows (740) 434-5041 as PKTX's company telephone number. Maybe you can get your questions answered there. $PKTX
Welcome back BPTrader. I think you are back just in time to see LIGA fulfill their business plan, although I think their business plan changed some over the years. $LIGA
This is from another board and I don't know if it applies to PKTX or not, but it is worth noting.
Amen!
Go Mr. Smith
Go $PKTX
gew59, Ascendia sounds like a perfect fit to help PKTX formulate their product and take it to market. It would be PKTX's start to generating revenue. Revenue would provide PKTX the funds to continue research on their other projects. PKTX's "partner" may not be Ascendia, but it would be one like Ascendia.
SPORT, I liked today's PKTX PR. It states what PKTX has already completed and what still has to be done to:
"moves us forward to commercialization of ProtoKinetix’s Dry Eye Disease program." – per Clarence Smith, CEO President
Now PKTX has to do the following to get the treatment of dry eye disease (DED) to make.
PKTX intends to complete the following activities:
1. Complete topical application formulation(s)
(PKTX already knows AAGP works. Now they need a company to formulate AAGP into a commercial product that can be offered to the public. The global pharmaceutical company will do the formulating) My words
2. Confirmatory DED efficacy tests
3. Drug product Good Lab Practice (GLP) IND-enabling safety toxicology
4. Communicate with Federal Drug Administration (FDA) on clinical trial design criteria
How long will these last four steps take? I am willing to wait to see.
$PKTX
I didn't expect a correction to the press release, I expected a correction to the PPS. When the PPS goes above 70, investors will take a little profit off the table and wait for the RSI to go back under 70. That is all I was saying. $PKTX
The reason I didn't make comments regarding information in LIGA's Annual Report is managements comments that they are waiting for their auditors to review their filings. Once the auditors review the general ledger and filings, LIGA management will have a firm idea on what their next moves will be. IMHO Go $LIGA
SPORT, if you look at the stock chart, you will see that RSI went over 70, which indicates that the stock is in an over bought position. No stock price keeps going up without a correction. It is healthy. $PKTX
https://stockcharts.com/h-sc/ui?s=PKTX&p=D&yr=0&mn=5&dy=0&id=p65358573826&a=886808237&listNum=1
I have been trying to do DD on companies that develop formulations, which is harder than I thought. I did come up with a company that recites the same words as PKTX's PR, but I doubt that it means anything.
I have a question regarding you comment on today's PKTX PR.
blh28, very interesting!
I see the "Subsidiaries" mentioned in the 2020 Annual Report added Horton World Solutions and BGTV. While it eliminated "Subsidiaries" Buck Lake Ranch, IRS Opportunities Zone and Identity Maxx Plus from the 2020 Annual Report. The three that were eliminated were in the 2019 Annual Report.
I believe the three were transferred to BGTV for accounting purposes but I would have to go back and reread the verbiage to be sure.
It does say that BGTV has an equity investment in 68 acres of land in Angola Indiana. Buck Lake is located in Angola, Indiana.
It sounds like LIGA is separating LIGA into two separate profit centers. One to hold BGTV and the other for home development.
Hope that helps. I would like to hear your thoughts.
saigai, I agree with the forward split. As PKTX's PPS increases into $XX, the shares will need to split, to keep the $XX within investor's buying range. Go $PKTX
It is just a matter of time before everything comes together. $LIGA
You are correct, investors see what they have in their PKTX investment and are adding more PKTX shares every chance they get. Go $PKTX
The way I see it, there is a lot more to LIG Assets than just the Brentwood TN Development. The problem is the Tioga Capital Development loan and Brentwood Development expenses are more than offsetting the profit made by BGTV. Like you said, once LIGA makes the Brentwood deal, the profit from LIGA's other Divisions will fall to the bottom line. I will look forward to seeing LIGA with a reported net income.
I was hoping LIGA would start releasing news once The Annual Report was filed. The news has to start at some time. Another PPS drop of 6.67%. All it would take is one or two PRs to reverse the trend.
I like it! Want to see more, PPS increases that is. $PKTX
I saw the activity on LIGA and thought something good was going on! $LIGA
AAGP Could Provide a Pathway to Treating This Chronic Autoimmune Disorder
Sjogren’s syndrome is an autoimmune condition in which a body’s own immune system attacks the cells in the moisture-producing salivary glands and tear ducts. The outcome of this autoimmune response is painfully dry eyes and mouth.
Linked to conditions such as rheumatoid arthritis, the condition may occur in tandem with other autoimmune disease or show up on its own. In addition to affecting the eyes and mouth, Sjogren’s can also affect the skin, hair, kidneys, and liver, causing conditions ranging from cavities to cirrhosis.
The two main symptoms of Sjogren's syndrome are:
Dry eyes. Your eyes might burn, itch, or feel gritty — as if there's sand in them.
Dry mouth. Your mouth might feel like it is full of cotton, making it difficult to swallow or speak.
The causes of Sjogren’s syndrome:
It appears that Sjogren’s, like other autoimmune disorders, is caused by a combination of genetic and environmental effects, possibly triggered by an infection, according to the Mayo Clinic. However, it’s unclear why some people are affected by the disease when others are not.
Autoimmune diseases are complex systems, but researchers are homing in on several risk factors for Sjogren’s: women are more likely than men to have it, as are people over 40 and those who also have a rheumatic disease such as lupus or rheumatoid arthritis.
My (scoobey-do) thought for the day
Research scientist soak eye cells in PKTX’s AAGP and then implant the eye cells into the Patient with Sjogren’s syndrome. The autoimmune system no longer recognizes the cells, in the moisture-producing salivary glands and tear ducts, as ones to be attacked. The eyes continue to produce tears to keep the eyes moist.
Sjogren’s has no known cure
Sjogren syndrome is estimated to affect 4 million people across the United States. Using AAGP, ProtoKinetix is exploring revolutionary new treatments that could alleviate the suffering caused by severe dry eyes.
Go PKTX! Go AAGP! Go Clarence Smith!
I sure don't know what the news will be. I wish it would be that PKTX ramped up production and started selling AAGP to research companies, but that isn't in PKTX's business plan. It will probably be that a big pharma bought us out. Go PKTX, make our day. Good luck to all PKTX investors.
Thank you. The stock chart can tell a lot about what is going on with the company. As long as more are buying than selling (Accum/Dist) all is good. $PKTX
If you follow this link, you should be able to see PKTX's stock chart for a couple of days.
https://stockcharts.com/h-sc/ui?s=PKTX&p=D&yr=0&mn=5&dy=0&id=p16940472540&a=886808237&listNum=1
Take a look at the Accum/Dist line at the bottom.
About LIGA Homes:
LIGA Homes unique residential and commercial developments utilize specially designed and manufactured recycled "element resistant" steel framing, in addition to toxic free magnesium oxide building materials and panels that are 100% mold, fungus, termite and rot resistant and fire resistant against temperatures up to 3500 degrees Fahrenheit as well as famed environmentalist Robert Plarr's exclusive "maximum rated" R-60 insulation -- combining to create disaster resistant materials and structures that can withstand up to a 7.5 magnitude earthquake and sustained gale force winds up to 175 MPH while negating damage caused by rain and flood exposure. With the addition of Plarr's green and renewable systems and products, LIGA Homes is now capable of providing affordable, fully sustainable and disaster resistant living environments – LIGA Homes is at the forefront of this new and improved direction for the green, sustainable and construction sectors.
For more information about LIGA Homes visit - www.LIGAHomes.com or contact the Company directly at 833-LIGAHOMES (833) 544-2463
Very true. I enjoy thinking about what things (PKTX) will look like in a year. Some may have shorter time frames, but all is good! $PKTX
AAGP® as a potential solution
A reliable treatment for the effects of Sjogren’s Syndrome has the potential to improve the lives of its sufferers, and ProtoKinetix is exploring the treatment potential of AAGP. As a proprietary glycopeptide, AAGP could heal or possibly even restore the cells that create moisture-producing tears necessary for properly functioning eyes. ProtoKinetix is exploring the application of AAGP within new eye drops that treat dry eyes.
Mike Guzzetta
Chief Financial Officer
New Albany, Ohio
Michael Guzzetta is a certified public accountant with an office located in Northeast Ohio. Prior to opening his practice, he spent 20 years in corporate management in the communications and energy industries. Guzzetta also served as an adjunct professor at Stark State College and taught courses in accounting, finance, business management and economics. He is a graduate of Stark State College and Walsh University, where he graduated magna cum laude with a bachelor’s degree in accounting. Guzzetta went on to earn master’s degrees in business administration from Capital University in Columbus, Ohio, and health care administration at Walsh University.
Clarence E. Smith
Chairman, Chief Executive Officer, President
Saint Marys, West Virginia
A serial entrepreneur and venture capitalist, Clarence Smith has decades of experience in executive business management, from inception and development to mergers and acquisitions. He has served on the ProtoKinetix board of directors for five years and currently holds the position of activist owner and major shareholder, collecting a $1 annual salary.
“AAGP is not a cure in itself but is an enhancement to existing technologies in regenerative medicine and cell survival. We are convinced it is poised to make significant advances in medical science.” – Clarence E. Smith
The ProtoKinetix leadership team
Committed to the pursuit of cell survival solutions, ProtoKinetix leaders manage diverse research initiatives with the mission to uncover innovative treatments to change patient lives.
Meet the team:
https://www.protokinetix.com/about/leadership-team/
AAGP® could provide a pathway to treating Sjogren’s Syndrome
Sjogren’s Syndrome is an orphan disease estimated to affect 4 million people across the United States, with no known cure. Using AAGP®, ProtoKinetix is exploring revolutionary new treatments that could help alleviate the suffering caused by severe dry eyes.
https://www.protokinetix.com/applications/ophthalmology/sjogrens-syndrome/
Why Longtime Investor Dr. Asim Raja believes in the potential of AAGP®
Dr. Raja knows the research ProtoKinetix is conducting could lead to billion-dollar applications in the fields of ophthalmology, dermatology, and even organ transplants. He encourages investors who believe in the market value of taking care of patients to join him.
https://www.protokinetix.com/why-dr-asim-raja-believes-in-the-potential-of-aagp/
Looking very good. $PKTX
Happy to see the new high! It should keep going higher and higher now. $PKTX
Photoreceptor precursor cell integration into rodent retina after treatment with novel glycopeptide PKX-001
Ishaq A. Viringipurampeer Anat Yanai Vahitha S. Nizamudheen Cheryl Y. Gregory-Evans Kevin Gregory-Evans
First published: 29 March 2021 https://doi.org/10.1002/term.3193
SUMMARY
Cell replacement therapy is emerging as an important approach in novel treatments for neurodegenerative diseases. Many problems remain, in particular improvements are needed in the survival of transplanted cells and increasing functional integration into host tissue. These problems arise because of immune rejection, suboptimal precursor cell type, trauma during cell transplantation, toxic compounds released by dying tissues and nutritional deficiencies. We recently developed an ex vivo system to facilitate identification of factors contributing to the death of transplanted neuronal (photoreceptor) and showed 2.8-fold improvement in transplant cell survival after pre-treatment with a novel glycopeptide (PKX-001). In this study we extended these studies to look at cell survival, maturation and functional integration in an in vivo rat model of rhodopsin-mutant retinitis pigmentosa causing blindness. We found that only when human photoreceptor precursor cells (PPCs) were pre-incubated with PKX-001 prior to transplantation, did the cells integrate and mature into cone photoreceptors expressing S-opsin or L/M opsin. In addition, ribbon synapses were observed in the transplanted cells suggesting they were making synaptic connections with the host tissue. Furthermore, optokinetic tracking and electroretinography responses in vivo were significantly improved compared to cell transplants without PKX-001 pre-treatment. These data demonstrate that PKX-001 promotes significant long-term stem cell survival in vivo, providing a platform for further investigation towards the clinical application to repair damaged or diseased retina.
This article is protected by copyright. All rights reserved.
About ProtoKinetix, Incorporated
ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.
For more Company information and to join our email listing visit our website.
https://mail.google.com/mail/u/0/?shva=1#inbox/FMfcgxwLtQNplzRsswWgMRRxkPDfbMxB
It sounds like MRNJ will be buying back all the flipper's stock. That's one way to get rid of the flippers.
I like the following:
"We have now completed both structural and functional studies in cell transplantation in model systems of blindness. Concurrent use of PKTX-001 has shown to significantly improve cell survival and integration into host tissue and will be a valuable asset in the field of regenerative medicine in the future". -- Dr. Kevin Gregory-Evans M.D., Ph.D.
Good morning Bird, I went back to the web-site and looked at the article again. It now says Apr 6 but no year. I will go back and see where it was announced that he resigned and post it.
I sent a letter to Mr. Robert Broderick, Esq. yesterday to see if he would provide any information. I believe, like a number of other companies, ADVT has just stopped filing 10-Ks to the SEC. but are still in business. IMHO
Happy to see that you are still following ADVT. Have a great day. $ADVT
I was doing some DD on ADVT and found a note that Darren Cherry resigned in August 2019. Does anyone know who the new CEO is?
Empowered Diagnostics
ImmunoPass Neutralizing Antibody Test
ImmunoPass™ SARS-Cov-2 Neutralizing Antibody (NAb) Rapid Test is a rapid lateral flow chromatographic immunoassay intended for the sem-iquantitative measurement of neutralizing antibody in human serum or plasma (sodium heparin, potassium and acid dextrose citrate).
The ImmunoPass™ SARS-Cov-2 Neutralizing Antibody (NAb) Rapid Test measures functional neutralizing antibodies (NAbs) within 10 minutes, unlike traditional test which require days. The ImmunoPass™ test kit does not utilize live biological materials and does not require the strict biosafety protocol associated with live virus samples.
https://empdx.net/immunopass-antibody-test/